Inflammatory Bowel Disease
Investigators: Ji Qiu, Ph.D., Garrick Wallstrom, Ph.D. and Gokhan Demirkan, Ph.D.
Collaborators:Jonathan Leighton, M.D. (Mayo Clinic)
|Who gets it?
What are the symptoms?
|How do we detect it now?
How is it currently treated?
|What are the current challenges?|
Autoimmune diseases arise when the body’s immune system attacks substances and tissues normally present in the body. Examples of autoimmune diseases include inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Patients with autoimmune diseases have identifiable antibodies against microbial and/or human proteins that can serve as potential serological biomarkers in the management of these patients. However, current IBD serologic markers have high false positive rates, which make them inefficient screening tests. Furthermore, these biomarkers cannot distinguish subtypes of IBD such as Ulcerative Colitis and Crohn’s disease.
We are working to identify markers in the blood using NAPPA that would provide a simple blood test to accurately diagnose inflammatory bowel disease and predict its clinical behavior for better patient management.